Cargando…

A swine model of acute thrombocytopenia with prolonged bleeding time produced by busulfan

Animal models of thrombocytopenia are indispensable for evaluating the in vivo efficacy of hemostatic agents, cryopreserved platelets, and artificial platelets, but no large animal models are available. In this study, we generated a swine model of acute thrombocytopenia with prolonged bleeding times...

Descripción completa

Detalles Bibliográficos
Autores principales: Abe, Tomoyuki, Kono, Shota, Ohnuki, Takahiro, Hishikawa, Shuji, Kunita, Satoshi, Hanazono, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Association for Laboratory Animal Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111837/
https://www.ncbi.nlm.nih.gov/pubmed/27333841
http://dx.doi.org/10.1538/expanim.16-0022
_version_ 1782467914132094976
author Abe, Tomoyuki
Kono, Shota
Ohnuki, Takahiro
Hishikawa, Shuji
Kunita, Satoshi
Hanazono, Yutaka
author_facet Abe, Tomoyuki
Kono, Shota
Ohnuki, Takahiro
Hishikawa, Shuji
Kunita, Satoshi
Hanazono, Yutaka
author_sort Abe, Tomoyuki
collection PubMed
description Animal models of thrombocytopenia are indispensable for evaluating the in vivo efficacy of hemostatic agents, cryopreserved platelets, and artificial platelets, but no large animal models are available. In this study, we generated a swine model of acute thrombocytopenia with prolonged bleeding times by administering the chemotherapeutic drug busulfan. First, we tested multiple doses of busulfan (4, 6, and 8 mg/kg) in pigs, and found that 6 mg/kg of busulfan is an optimal dose for producing a safe and moderate thrombocytopenia, with a platelet count of less than 30,000/µl. The pigs administered 6 mg/kg of busulfan (n=8) reached half their initial counts at day 7, counts below 30,000/µl at day 12, and their nadirs at day 15 (on average). The minimal platelet count was 14,000/µl. With this dose of busulfan (6 mg/kg), bleeding times were significantly prolonged in addition to the decrease in platelet counts (r=−0.63, P<0.01), while there were no cases of apparent hemorrhage. White blood cell counts were maintained at over 5,000/µl, and there were no infections or other adverse events including anemia or appetite or body weight loss. All pigs were sacrificed on day 16, with subsequent examination showing a significant reduction in cellularity and colony-forming units in the bone marrow, indicating that thrombocytopenia was the result of myelosuppression. In summary, administration with 6 mg/kg of busulfan induces safe and moderate thrombocytopenia with a prolonged bleeding time in swine.
format Online
Article
Text
id pubmed-5111837
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Japanese Association for Laboratory Animal Science
record_format MEDLINE/PubMed
spelling pubmed-51118372016-11-17 A swine model of acute thrombocytopenia with prolonged bleeding time produced by busulfan Abe, Tomoyuki Kono, Shota Ohnuki, Takahiro Hishikawa, Shuji Kunita, Satoshi Hanazono, Yutaka Exp Anim Original Animal models of thrombocytopenia are indispensable for evaluating the in vivo efficacy of hemostatic agents, cryopreserved platelets, and artificial platelets, but no large animal models are available. In this study, we generated a swine model of acute thrombocytopenia with prolonged bleeding times by administering the chemotherapeutic drug busulfan. First, we tested multiple doses of busulfan (4, 6, and 8 mg/kg) in pigs, and found that 6 mg/kg of busulfan is an optimal dose for producing a safe and moderate thrombocytopenia, with a platelet count of less than 30,000/µl. The pigs administered 6 mg/kg of busulfan (n=8) reached half their initial counts at day 7, counts below 30,000/µl at day 12, and their nadirs at day 15 (on average). The minimal platelet count was 14,000/µl. With this dose of busulfan (6 mg/kg), bleeding times were significantly prolonged in addition to the decrease in platelet counts (r=−0.63, P<0.01), while there were no cases of apparent hemorrhage. White blood cell counts were maintained at over 5,000/µl, and there were no infections or other adverse events including anemia or appetite or body weight loss. All pigs were sacrificed on day 16, with subsequent examination showing a significant reduction in cellularity and colony-forming units in the bone marrow, indicating that thrombocytopenia was the result of myelosuppression. In summary, administration with 6 mg/kg of busulfan induces safe and moderate thrombocytopenia with a prolonged bleeding time in swine. Japanese Association for Laboratory Animal Science 2016-06-21 2016 /pmc/articles/PMC5111837/ /pubmed/27333841 http://dx.doi.org/10.1538/expanim.16-0022 Text en ©2016 Japanese Association for Laboratory Animal Science http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License.
spellingShingle Original
Abe, Tomoyuki
Kono, Shota
Ohnuki, Takahiro
Hishikawa, Shuji
Kunita, Satoshi
Hanazono, Yutaka
A swine model of acute thrombocytopenia with prolonged bleeding time produced by busulfan
title A swine model of acute thrombocytopenia with prolonged bleeding time produced by busulfan
title_full A swine model of acute thrombocytopenia with prolonged bleeding time produced by busulfan
title_fullStr A swine model of acute thrombocytopenia with prolonged bleeding time produced by busulfan
title_full_unstemmed A swine model of acute thrombocytopenia with prolonged bleeding time produced by busulfan
title_short A swine model of acute thrombocytopenia with prolonged bleeding time produced by busulfan
title_sort swine model of acute thrombocytopenia with prolonged bleeding time produced by busulfan
topic Original
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111837/
https://www.ncbi.nlm.nih.gov/pubmed/27333841
http://dx.doi.org/10.1538/expanim.16-0022
work_keys_str_mv AT abetomoyuki aswinemodelofacutethrombocytopeniawithprolongedbleedingtimeproducedbybusulfan
AT konoshota aswinemodelofacutethrombocytopeniawithprolongedbleedingtimeproducedbybusulfan
AT ohnukitakahiro aswinemodelofacutethrombocytopeniawithprolongedbleedingtimeproducedbybusulfan
AT hishikawashuji aswinemodelofacutethrombocytopeniawithprolongedbleedingtimeproducedbybusulfan
AT kunitasatoshi aswinemodelofacutethrombocytopeniawithprolongedbleedingtimeproducedbybusulfan
AT hanazonoyutaka aswinemodelofacutethrombocytopeniawithprolongedbleedingtimeproducedbybusulfan
AT abetomoyuki swinemodelofacutethrombocytopeniawithprolongedbleedingtimeproducedbybusulfan
AT konoshota swinemodelofacutethrombocytopeniawithprolongedbleedingtimeproducedbybusulfan
AT ohnukitakahiro swinemodelofacutethrombocytopeniawithprolongedbleedingtimeproducedbybusulfan
AT hishikawashuji swinemodelofacutethrombocytopeniawithprolongedbleedingtimeproducedbybusulfan
AT kunitasatoshi swinemodelofacutethrombocytopeniawithprolongedbleedingtimeproducedbybusulfan
AT hanazonoyutaka swinemodelofacutethrombocytopeniawithprolongedbleedingtimeproducedbybusulfan